Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab + bevacizumab + platinum chemotherapy followed by pembrolizumab + bevacizumab + olaparib in platinum-sensitive recurrent ovarian cancer
jRCT2031210397Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, bevacizumab and olaparib in ovarian cancer, sponsored by Merck & Co. Primary endpoint: Two-year progression-free survival rate. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on jRCT2031210397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210397.